Steven E Nissen MD
Preventive Cardiology
Professor of Medicine, Cleveland Cl College of Medicine/Case West Res
Join to View Full Profile
9500 Euclid AveCleveland, OH 44195
Phone+1 800-223-2273
Fax+1 216-445-6855
Dr. Nissen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Steven Nissen is a cardiologist in Cleveland, OH and is affiliated with Cleveland Clinic. He received his medical degree from University of Michigan Medical School and has been in practice 39 years. He specializes in preventive cardiology and is experienced in general cardiology, lipid disorders, preventive cardiology, hypertension, and coronary artery disease. He has more than 500 publications and over 90,000 citations.
Education & Training
University of Kentucky College of MedicineFellowship, Cardiovascular Disease, 1981 - 1983
University of Michigan Medical SchoolClass of 1978
Certifications & Licensure
OH State Medical License 1992 - 2026
CA State Medical License 1980 - 1993
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2004-2014
- Northern Ohio Live Castle Connolly, 2006-2009
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia Start of enrollment: 2014 Oct 30
- The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis Start of enrollment: 2017 Jan 01
- Supplements, Placebo, or Rosuvastatin Study Start of enrollment: 2021 Apr 23
Publications & Presentations
PubMed
- Association of Testosterone-Induced Increase in Neutrophil and Monocyte Counts with Thromboembolic Events: The TRAVERSE Trial: Testosterone-Induced Increase in Neutrop...Thiago Gagliano-Jucá, Karol M Pencina, Yili Valentine Shang, Thomas G Travison, A Michael Lincoff
American Heart Journal. 2025-04-15 - Design and rationale of Lp(a)HORIZON trial: Assessing the effect of Lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and ele...Leslie Cho, Stephen J Nicholls, Børge G Nordestgaard, Ulf Landmesser, Sotirios Tsimikas
American Heart Journal. 2025-04-02 - Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: Insights from HUYGENS.Masashi Fujino, Giuseppe Di Giovanni, Julie Butters Bhsc, Yu Kataoka, Thomas Hucko
Atherosclerosis. 2025-04-01
Journal Articles
- Coronary Revascularization StrategiesSteven E Nissen, Faisal G Bakaeen, JAMA
- Effect of C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients with High-Risk Vascular DiseaseSteven E Nissen, Jeffrey S Riesmeyer, JAMA Cardiology
- Original Investigation Effect of Evolocumab on Coronary Plaque CompositionSteven E Nissen, Ransi Somaratne, Rishi Puri, Christie M Ballantyne, ScienceDirect
- Join now to see all
Authored Content
- Coronary Revascularization StrategiesJuly 2020
- Effect of C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients with High-Risk Vascular DiseaseJuly 2020
- Effect of C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients with High-Risk Vascular DiseaseJuly 2020
- Effect of C-reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients with High-Risk Vascular DiseaseJuly 2020
- ADCY9 Genetic Variants and Cardiovascular Outcomes with Evacetrapib in Patients with High-Risk Vascular DiseaseJuly 2018
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsMarch 2017
- Join now to see all
Press Mentions
Genetic Cholesterol Eliminated by New Drug, Reducing Heart Attack Risk, Study FindsApril 12th, 2025- ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(A)April 10th, 2025
- Lepodisiran Injection Cuts Lipoprotein(A) by 94% in TrialApril 2nd, 2025
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
